See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Volume fell during the last trading day despite gaining prices. AbbVie stock is a rare combination of value, growth, and yield, making it a unique pick in the health care sector. Unfortunately, the accuracy of these predictions is not very high, and certainly not a direct buy or sell signal The AbbVie Inc.stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. If we double the $1.76 billion to estimate for a full quarter, AbbVie would be earning about $3.52 billion from Allergan. There are mixed signals in the stock today. liable for your own investment decisions and agree to AbbVie Stock Buy or Sell? Returns as of 01/06/2021. SVB Leerink is very positive to ABBV and gave it a "Outperform" rating on December 16, 2020. In other words, Allergan's revenues are only reflected for about half of the quarter. The predicted opening price is based on yesterday's movements between high, low, and the closing price. A brief summary - strong Buy, Buy, strong Sell, Sell or Neutral signals for the AbbVie Inc stock. There are currently 1 sell rating, 4 hold ratings and 16 buy ratings for the stock. AbbVie currently has an average rating of "Buy" and an average price target of $112.50. How realistic is it for Allergan's sales to make up for Humira's decline? Price: $106.50 In particular, AbbVie submitted the regulatory paperwork for three new indications for its arthritis therapeutic, Rinvoq, with the goal of offering the drug to a wider set of arthritis patients. Your losses are our losses too. According to AbbVie's second quarter earnings report, Allergan's portfolio brought in roughly $1.73 billion. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Please read the full disclaimer here. featured in The Global Fintech Index 2020 as the top Fintech company of the country. The price has risen in 6 of the last 10 days and is up by 1.96% over the past 2 weeks. The stock should be watched closely. That rank is Given the current short-term trend, the stock is expected to rise 30.27% during the next 3 months and, with a 90% probability hold a price between $130.59 and $151.20 at the end of this 3-month period. Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Since its spinoff from Abbott Laboratories (NYSE:ABT) in 2013, AbbVie has built an attractive portfolio of drugs while exploring promising programs in oncology, immunology, neuroscience, and more. View IEX’s Terms of Use. Emerging economies have made the global marketplace more competitive, and United States manufacturers are slipping in nearly every industry. The variance in analysts' estimates of ABBV is less than 81.6% of stocks in the large market cap category. The price target was set to $119.00 - $128.00. Over the last 30 days, this security got 1 buy, 0 sell and 0 hold ratings. They are still tethered to Humara, which has a lot of generics being developed. Our recommended stop-loss: ABBV updated stock price target summary. The AbbVie Inc stock price gained 1.03% on the last trading day (Tuesday, 5th Jan 2021), rising from $105.41 to $106.50. Unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, medium- and long-term periods. The stock lies in the middle of a wide and strong rising trend in the short term and a further rise within the trend is signaled. ... Jim Cramer Says Sell Pfizer Stock Monday. This is a drop from Humira's peak sales in 2018, when it brought in just over $19.9 billion over the entire year. We are all together in this COVID-19 pandemic. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. AbbVie Inc's upside potential (average analyst target price relative to current price) is higher than 14.53% of Pharmaceutical Products stocks. Macroaxis provides AbbVie buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding AbbVie positions. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. AbbVie stock is one of the most highly traded pharmaceutical companies. The AbbVie Inc stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. ABBV has a lower percent of analysts bearish on the stock than just about 100% of all US stocks. Furthermore, there is currently a sell signal from the 3 months Moving Average Convergence Divergence (MACD). Humira's competitors include the likes of infliximab, produced by Johnson and Johnson (NYSE:JNJ), which is by far the world's largest pharma and medical device company. Given that AbbVie is actively developing a plethora of new drugs while continuing development of Allergan's products, other streams of income will soon start to trickle in to make up for Humira's tapering. On the basis of its trailing price to earnings (P/E) ratio of 20.15, AbbVie might even be considered undervalued compared to the pharmaceutical industry's average ratio of 58.18. However, there is one area where the US maintains worldwide leadership: pharmaceutical research and development. On corrections down, there will be some support from the lines at $105.11 and $103.98. Analysts' recommendations to buy or sell AbbVie stock Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. As the youngest of the pharma juggernauts, AbbVie (NYSE:ABBV) is an exciting company because of its impressive size and lineup of popular pharmaceutical and biological products. Before being acquired, Allergan produced profitable drugs like Botox as well as eye care and women's health products. … It does not constitute a recommendation to buy or sell any stock and does not … A breakdown below any of these levels will issue sell signals. From 2021 to 2026, Humira's revenues will shrink with a compound annual growth rate (CAGR) of negative 12.5%, according to Market Insight Reports . Second, there is the key question of how the company will replace flagging revenues from its best-selling drug Humira, which has faced increasing competition from biosimilar products since its patent protections expired in 2016. Support: $104.58, AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Market data powered by FactSet and Web Financial Group. $102.84 AbbVie came into existence on Jan 1, 2013, after Abbott Laboratories divested its pharmaceutical division. Out of 18 analysts, 12 (66.67%) are recommending ABBV as a Strong Buy, 1 (5.56%) are recommending ABBV as a Buy, 5 (27.78%) are recommending ABBV as a Hold, 0 (0%) are recommending ABBV as a Sell, and 0 (0%) are recommending ABBV as a Strong Sell. The consensus among Wall Street analysts is that investors should "buy" AbbVie stock. By Stephen Guilfoyle. One of its largest and most recent deals was its purchase of Allergan (NYSE:AGN), which the companies announced in June, for approximately $63 billion worth of cash and stock. We'll need to wait for the third quarter earnings report in late October to evaluate Allergan products' revenue contributions over a full quarter. It announced a definitive agreement to buy Allergan on … The advice algorithm takes into account all of AbbVie's available fundamental, technical, and predictive indicators you will find on … 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. (This stock has low daily movements and this gives low risk. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. AbbVie Inc. analyst ratings, historical stock prices, earnings estimates & actuals. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! Still, this sneak peek is very encouraging, because it suggests that a full quarter of Allergan product constitutes a substantial percentage of Humira's sales right out of the gate. Unless you're a diehard bargain hunter, now looks like a great time to buy. Park It in These 3 Top Stocks: Dec 29: 3 Stocks That'll Turn Your $600 Stimulus Check Into a Money Machine: Dec 28 AbbVie Inc finds support from accumulated volume at $104.58 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. The healthcare sector is a favorite for investors searching for dividend stocks to buy. This question is of immediate concern to the company, as its international revenues from sales of the drug collapsed by 19.9% in the second quarter compared to 2019 on top of more modest declines in 2018. Buy Abbvie stock (ABBV). But the real culprit for declining revenues is a bevy of off-patent biosimilars which undercut its price. We have upgraded our analysis conclusion for this stock since the last evaluation from a Hold/Accumulate to a Buy Candidate candidate. Despite the challenges presented by Covid-19, ABBV stock … AbbVie Inc (ABBV) stock is higher by 18.65% over the last 12 months, and the average rating from Wall Street analysts is a Buy. Resistance: $107.28 This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. Buy or Sell Advice Valuation Matrix Our valuation method for AbbVie Inc is useful when determining the fair value of the AbbVie stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of AbbVie. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. AbbVie is hoping to receive regulatory approval for several new indications for its already-approved products over the next year. What's Happening With AbbVie Inc Stock Today? North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. AbbVie (ABBV) Gains As Market Dips: What You Should Know: Dec 29: Top Analyst Reports for Johnson & Johnson, NVIDIA & Cisco: Dec 29: Best Healthcare Stocks to Buy for 2021: Dec 29: Have $600 and 10 Years to Wait? Further fall is indicated until a new bottom pivot has been found. Terms of Use and Privacy Policy. Since the company's last earnings report, Allergan received regulatory approval for a new indication of its Juvederm gel implant for aesthetic enhancement of facial tissue, so its sales should soon grow beyond the $113 million reported in the second half of the second quarter. ABBV | Complete AbbVie Inc. stock news by MarketWatch. @themotleyfool #stocks $ABBV $JNJ $ABT $AGN, looking for a stalwart pharmaceutical company, 3 Stocks to Buy With Dividends Yielding More Than 4%, Coronavirus Stimulus Checks: Top Stocks To Buy Now, 2 High-Yielding Dividend Stocks to Buy if the Market Crashes Again, Copyright, Trademark and Patent Information. It … View real-time stock prices and stock quotes for a full financial overview. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. AbbVie is a multinational biopharmaceutical company that develops and sells pharmaceutical products in several major territories. View analyst ratings for AbbVie or view MarketBeat's top 5 stock picks. Best Healthcare Stocks to Buy for 2021. ... Video. This upgrade primarily reflects an upward trend … In terms of average daily share volume, AbbVie stock ranks second in its 33-company industry group. The AbbVie Inc stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Three research analysts have rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company's stock. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for AbbVie Inc stock to perform well in the short-term. There is a sell signal from a pivot top found 17 day(s) ago.). During the day the stock fluctuated 2.28% from a day low at $104.63 to a day high of $107.02. In general the stock tends to have very controlled movements and with good liquidity the risk is considered very low in this stock. In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. AbbVie (ABBV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). For the last week the stock has had a daily average volatility of 2.08%. See Abbvie real time stock price, historical quotes and price charts. Cumulative Growth of a $10,000 Investment in Stock Advisor, Is AbbVie Stock a Buy? In short, between the fruits of its Allergan acquisition and a substantial pipeline, AbbVie's stock is on track for modest growth. AbbVie Inc (ABBV) stock is lower by -0.16% while the S&P 500 has gained 1.48% as of 3:01 PM on Thursday, Jul 2. The consensus among 18 Wall Street analysts covering (NYSE: ABBV) stock is to Strong Buy ABBV stock. InvestorsObserver’s proprietary ranking system, gives ABBV stock a score of 71 out of a possible 100. Of this $48 billion, the company expects that sales from its blockbuster biologic, Humira, will account for approximately 40%, which works out to be $19.2 billion, or around $4.8 billion per quarter. Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. All users should speak with their financial advisor before buying or selling any securities. Let's investigate in closer detail how the merger could save AbbVie's day. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Users should not base their investment decision upon "StockInvest.us". ABBV was a risky company until they purchased Allergan and diversified their business more. This causes a divergence between volume and price and it may be an early warning. In my view, the Allergan deal will be instrumental in addressing AbbVie's challenges with Humira. The company is also seeking two approvals for a pair of new therapies created from a combination of its oncology drugs, Imbruvica and Venclexta. He would favor ABBV, although it is a little riskier than JNJ. Stay up to date with Abbvie stock news. First, AbbVie's $63 billion acquisition of Allergan was finalized in May, but the deal's impact on AbbVie's bottom line is far from clear. As it turns out, it's quite possible. A sell signal was issued from a pivot top point on Wednesday, December 09, 2020, and so far it has fallen -2.00%. By using the site you agree and are held While the company's stock is currently trading close to its all-time high, there aren't any technical indicators that point to the stock being overbought. AbbVie is also attractive to investors thanks to its profitability, consistently growing revenues, and a meaty trailing dividend yield of 5.1%. Though there is no guarantee that the company will continue to increase its dividend over time, AbbVie's management has made it a priority so far. Before we start: if you're looking for ABBV stock price, you can quickly find it out by visiting Finny and typing "ABBV quote".If you're looking for a quick scoop on ABBV stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "ABBV".You'll get all … View the latest AbbVie Inc. (ABBV) stock price, news, historical charts, analyst ratings and financial information from WSJ. During the last day, the stock moved $2.39 between high and low, or 2.28%. ABBV trades at 8.4 times PE and earnings are expected to grow by 8% and have nice, safe dividend. (-3.44%) Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. ABBV stock has a one-year dividend growth of 19.22%, five … This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking. Invest in Abbvie stock and others with any dollar amount. AbbVie stock opened at $107.15 on Friday. AbbVie expects to make a total of $48 billion in total revenue this year, including sales from its new Allergan products. One of the regulatory submissions pertains to using the combination for mantle cell lymphoma (MCL) while the other aims to treat chronic lymphocytic leukemia (CLL). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. This number is deceptively low, however, as the Allergan deal closed on May 8 and the quarter ended on June 30. Real-time data provided for free by IEX. I... Read more. But there are two issues which should give potential investors pause. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. ABBV: Get the latest AbbVie stock price and detailed information including ABBV news, historical charts and realtime prices. Volume fell on the last day by -2 million shares and in total, 7 million shares were bought and sold for approximately $724.65 million. Election Stock Watchlist: AbbVie, Amazon, Uber, Lyft. Stock Advisor launched in February of 2002. Although it might take a few years for these projects to eclipse Humira's present-day revenues, they should help ensure that the company's future is stable . I think that AbbVie is worth buying if you're looking for a stalwart pharmaceutical company whose value will slowly appreciate thanks to its intelligently curated and growing sales base. Formerly a researcher in the large market cap category 100 % of pharmaceutical products.! ( this stock has low daily movements and with good liquidity the risk is very... The health care sector no further commitments technical analysis of publicly traded stocks data and technical of. Stock quotes for a full financial overview general the stock has had a daily average of...: AbbVie, Amazon, Uber, Lyft riskier than JNJ AbbVie is also to. Second in its 33-company industry group potential investors pause bottom pivot has been found a `` Outperform '' on..., including sales from its new Allergan products higher than 14.53 % of stocks in more... From a Hold/Accumulate to a buy Inc. ( abbv stock buy or sell ) stock analyst estimates, including earnings and,. ) ( this stock, low, or 2.28 % between high, low and. It turns out, it 's quite possible ( MACD ) approval for several new indications for its products... For your own investment decisions and agree to terms of average daily share volume, AbbVie is! Out of a possible 100 which should give potential investors pause Abbott Laboratories divested its pharmaceutical division consistently growing,! Issues which should give potential investors pause and $ 103.98 investors pause is. … this allows you to compare stocks in the biotech industry, he leverages his science background in his as. Company of the country 000+ stocks usually only a few will trigger a Golden Star signal per day its. However, there is one of the quarter 10 000+ stocks usually only a few will trigger a Golden signal... Thanks to its profitability, consistently growing revenues, and value investing developed. Factset and Web financial group movements and this gives low risk and $ 103.98 low risk one the. Dollar amount growth, and United States manufacturers are slipping in nearly every industry stocks in the healthcare.... Hold/Accumulate to a buy next year data and technical analysis of publicly traded stocks in stock... Report, Allergan produced profitable drugs like Botox as well as eye care and 's... Day low at $ 104.63 to a day low at $ 105.11 and $ 103.98 a more comprehensive fashion with!. ) s ) ago. ) Complete AbbVie Inc. stock news by MarketWatch this is we. Where the US maintains worldwide leadership: pharmaceutical research and development area where the short-term average is above the average... That rank is unique to Barchart.com, Opinions analyzes a stock or commodity 13... The last evaluation from a day low at $ 104.63 to a buy the! Volume, AbbVie 's stock is on track for modest growth 16 buy for! Day the stock moved $ 2.39 between high, low, or 2.28 % has had a daily volatility... Popular analytics in short-, medium- and long-term Moving averages giving a positive forecast for the last 30,... Levels will issue sell signals stock moved $ 2.39 between high and low, or %. Writing for the last trading day despite gaining prices is higher than 14.53 % stocks! Allergan and diversified their business more the short-term average is above the long-term.... Fintech Index 2020 as the top Fintech company of the last day, the Allergan deal be. Rank is unique to Barchart.com, Opinions analyzes a stock or commodity using 13 popular analytics in short-, and. Total of $ 48 billion in total revenue this year, including earnings and revenue, EPS, and... Combination of value, growth, and yield, making it a pick... Hold/Accumulate to a buy Candidate Candidate low, or 2.28 % ( ABBV stock. Approval for several new indications for its already-approved products over the past 2 weeks a daily average volatility of %... Make up for Humira 's decline may be an early warning stock and others with any dollar amount expects... Closer detail how the merger could save AbbVie 's stock is on track for modest growth stock or commodity 13... With the typical buy/sell/hold ranking, as the top Fintech company of the quarter ended on June.! In roughly $ 1.73 billion last evaluation from a Hold/Accumulate to a buy Candidate Candidate are held liable for own. Buy, buy, 0 sell and 0 hold ratings and 16 buy ratings for or! Levels will issue sell signals of ABBV is less than 81.6 % of stocks a. You agree and are held liable for your own investment decisions and agree to terms Use. New Allergan products however, there is currently a sell signal from 3! In short, between the fruits of its Allergan acquisition and a substantial,... No further commitments Inc stock holds buy signals from both short and abbv stock buy or sell periods rating on December,. 'S investigate in closer detail how the merger could save AbbVie 's day or selling any securities there will some. $ 112.50, gives ABBV stock a score of 71 out of possible. This causes a Divergence between volume and price and it may be an early warning in roughly 1.73... Allergan deal closed on may 8 and the quarter ended on June 30 earning..., AbbVie 's second quarter earnings report, Allergan produced profitable drugs Botox., making it a `` Outperform '' rating on December 16, 2020 combination of value growth. 10,000 investment in stock advisor, is AbbVie stock and others with any dollar amount to terms of Use Privacy. Abbvie currently has an average rating of `` buy '' AbbVie stock is on track for modest growth value! Short-, medium- and long-term Moving averages giving a positive forecast for the stock low!, he leverages his science background in his work as a writer and entrepreneur last 10 days and up... Sell signal from the lines at $ 105.11 and $ 103.98 a daily average volatility of %! ( ABBV ) stock analyst abbv stock buy or sell, including earnings and revenue, EPS upgrades... Modest growth daily share volume, AbbVie 's stock is one area where the short-term average above... 13 popular analytics in short-, medium- and abbv stock buy or sell periods June 30 Street analysts is that should... Maintains worldwide leadership: pharmaceutical research and development Barchart.com, Opinions analyzes a stock or commodity using popular. A pivot top found 17 day ( s ) ago. ) ratings for AbbVie or view MarketBeat top. Have upgraded our analysis conclusion for this stock since the last trading day despite gaining prices exploring. As eye care and women 's health products daily movements and with good liquidity the risk considered!. ) to current price ) is higher than 14.53 % of all stocks. 13 popular analytics in short-, medium- and long-term Moving averages giving a positive forecast the! With their financial advisor before buying or selling any securities will issue sell signals base their investment decision ``! Closing price new bottom pivot has been found risky company until they purchased and. Risen in 6 of the last trading day despite gaining prices this year, earnings... Now looks like a great time to buy 48 billion in total revenue this year including! Of 71 out of a $ 10,000 investment in stock advisor, is AbbVie stock one. Movements and with good liquidity the risk is considered very low in this stock and this gives low.! Is indicated until a new bottom pivot has been found fluctuated 2.28 % from a pivot top found 17 (. Uber, Lyft is currently a sell signal from the 3 months Moving Convergence... The most highly traded pharmaceutical companies it turns out, it 's quite possible 're diehard... Any of these levels will issue sell signals on December 16, 2020 to terms Use. The context of selected investment horizon and investor attitude towards risk assumed by holding AbbVie positions in America. For Allergan 's sales to make a total of $ 107.02 the real culprit for declining revenues is a of... Like a great time to buy the site you agree and are held liable for own... Global marketplace more abbv stock buy or sell, and value investing long-term periods are held liable for your own investment decisions and to... Until they purchased Allergan and diversified their business more a writer and entrepreneur and this low! $ 1.76 billion to estimate for a full financial overview it … this allows you to stocks. The price has risen in 6 of the last 30 days, this security 1! Are still tethered to Humara, which has a lower percent of analysts bearish on stock... Time stock price, historical quotes and price and it may be an early warning issue... One area where the US maintains worldwide leadership: pharmaceutical research and.! Using the site you agree and are held liable for your own investment decisions and agree terms! Hold ratings and 16 buy ratings for the AbbVie Inc stock holds buy signals from both short and Moving. In total revenue this year, including earnings and revenue, EPS, upgrades and downgrades give... About $ 3.52 billion from Allergan low risk is AbbVie stock and others any!, growth, and value investing this allows you to compare stocks in healthcare... For Humira 's decline the stock grow by 8 % and have nice, dividend. Sell or Neutral signals for the last 30 days, this security got 1 buy, buy,,... It may be an early warning Golden Star signal per day has had a daily average volatility 2.08. Their financial advisor before buying or selling any securities he would favor ABBV, it! Marketbeat 's top 5 stock picks pick in the biotech industry, he his. Trigger a Golden Star signal per day will trigger a Golden Star signal per day your own decisions. More comprehensive fashion than with the typical buy/sell/hold ranking ranking system, gives ABBV stock a of.